Allopurinol for CVD in CKD (AvoiD-CKD): A double blind, randomized controlled trial - AvoiD-CKD

Head Department of Nephrology PGIMER0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1.Age 18-75 years
•2.eGFR by CKD-EPI 10-45 ml/min/1.73m2
•3.Serum uric acid levels more than or equal to 6 mg/dL
•4.Clinically stable course as judged by the treating physician for last 3 months

•1.Receiving long-term maintenance dialysis
•2.Receiving immunosuppressive therapy
•3.Diagnosis of gout
•4.Diagnosis of chronic liver disease
•5.Anticipated to need long-term renal replacement therapy within 6 months as judged by treating physician
•6.Poor functional status as judged by the treating physician
•7.Life expectancy <1 year as judged by the treating physician
•8.Pregnancy or planning of pregnancy in case of females
•9.Blood Hemoglobin <8 g/dL
•10.History of having received any type of organ transplant
•11.Diagnosis of malignancy
•12.History of allergy/hypersensitivity reaction to allopurinol
•13.Having received hypouricemic drug in last 30 days

发起方

Head Department of Nephrology PGIMER